This test is most useful if any of these apply to you.
Your gut is home to trillions of bacteria, and a small subset of them do one of the most important jobs in your entire digestive system. They take the fiber you eat and turn it into butyrate, a fatty acid that fuels the cells lining your colon, tightens the gut barrier, and calms inflammation. Butyrivibrio crossotus is one of these butyrate-producing species, and research keeps pointing to its abundance as a soft signal of a well-functioning gut ecosystem.
This is an exploratory marker, not an established clinical test. There are no official cutpoints, no guidelines telling your doctor to order it, and no single disease it diagnoses. What it can do is give you a window into a pathway that standard blood tests never touch, and a number you can track as you change your diet.
Butyrivibrio crossotus (often shortened to B. crossotus) belongs to a family of anaerobic bacteria that thrive in the oxygen-free environment of your colon. It specializes in breaking down the fibers and complex plant sugars that your own digestive enzymes cannot touch. The end product of that fermentation is butyrate, a short-chain fatty acid that the cells of your colon use as their primary fuel source.
Butyrate does more than feed your gut lining. It helps maintain the tight junctions between intestinal cells, which is how your gut keeps bacterial fragments and food particles from leaking into your bloodstream. It also sends anti-inflammatory signals to immune cells throughout the body. The abundance of B. crossotus in your stool reflects, in part, how much of this fermentation work is getting done inside you.
The largest piece of evidence linking this bacterium to human health comes from a cross-cohort analysis of 8,117 people across ten countries. B. crossotus was depleted in people with type 2 diabetes, alongside other fiber-fermenting, butyrate-producing species. The pattern was consistent enough that the authors grouped B. crossotus among a cluster of microbes that appear to be protective against glucose dysregulation.
What this means for you: if you already have elevated blood sugar or a family history of type 2 diabetes, low abundance of this bacterium may be one more piece of the puzzle showing that your gut is not supporting your metabolism the way it should. It is not a diagnostic test, but it is a clue about which direction to push your diet.
In a cohort of 1,013 adults aged 32 to 42, B. crossotus clustered with other bacteria involved in the balance between two arms of the immune system that scientists call Th1 and Th2 inflammation. This was not a causation study, but it suggests your abundance of this species may track, loosely, with how well your immune system maintains its inflammatory set point during the decades when early aging changes are beginning.
A study of 1,472 adults found that people with glaucoma had lower levels of Butyrivibrio and other butyrate-producing species compared to controls. Higher Butyrivibrio abundance was associated with lower pressure inside the eye and less damage to the optic nerve. Associations weakened after strict statistical correction, so this is a lead rather than a conclusion, but it points toward a possible gut-eye axis worth watching.
Not every study finds that more B. crossotus is better. Mendelian randomization work, which uses genetic variants to infer causation, has linked higher levels to increased kidney cancer risk, while also linking higher levels to lower risk of primary sclerosing cholangitis, an autoimmune bile duct disease. A study of periodontitis also found higher levels in people with gum disease. And in a 12-week trial of caloric restriction plus high-intensity interval training in obese adults, a close relative called Butyrivibrio fibrisolvens (not B. crossotus specifically) actually decreased as participants lost weight and improved their liver enzymes.
The framework that makes all of this consistent: B. crossotus is not a simple good-number or bad-number marker. It is an indicator of one slice of a broader bacterial community, and different combinations of gut bacteria can produce different outcomes in different diseases. High levels in a fiber-rich, plant-heavy diet pattern likely reflect something very different from high levels in a gut dealing with chronic inflammation. Treat this bacterium as one data point inside a microbial ecosystem, not as a verdict.
A study of 2,444 Hispanic and Latino adults found that people following healthy dietary patterns (the alternate Mediterranean diet, the Healthy Eating Index, and the healthful plant-based index, three commonly used scoring systems for diet quality) had higher abundance of B. crossotus and other fiber-fermenting bacteria. In a separate study of 68 people with constipation, an anti-inflammatory diet was associated with lower B. crossotus. These results may seem contradictory, but they likely reflect the different gut environments in a general population versus people with sluggish transit.
There are no standardized clinical cutpoints for B. crossotus. This is a research-grade measurement, not a diagnostic test, so labs report your abundance relative to a reference population or as a percentage of your total gut bacteria. Values vary widely between labs depending on whether the assay uses 16S ribosomal RNA sequencing (a method that identifies bacteria by a specific gene), shotgun metagenomic sequencing (which reads all the DNA in your sample), or quantitative PCR (a method that counts copies of a specific DNA sequence).
What this means for interpretation: compare your result only against prior results from the same lab using the same method. A number in isolation, without context from diet history and a repeat measurement, tells you very little.
A single stool sample captures a snapshot of a community that shifts daily with what you eat, how you sleep, whether you have been sick, and what medications you take. The value of this test is almost entirely in the trend. Get a baseline, make whatever dietary change you are considering (more fiber, more fermented foods, more plant diversity), then retest in 3 to 6 months. Once you find a pattern that works, retest at least annually to make sure the shift is holding.
Because this is a Tier 3 marker, the trend matters even more than it does for established tests. You are building your own baseline database, and watching how your gut responds to your interventions, rather than comparing yourself to a published cutoff that does not yet exist.
If your abundance is low, the most useful next step is to look at this result alongside other markers of metabolic and gut health. A full stool panel can show you whether other butyrate-producing bacteria (like Faecalibacterium prausnitzii and Roseburia species) are also depleted, which strengthens the signal. Pairing this with a short-chain fatty acid measurement in stool gives you a direct read on whether the bacteria you do have are actually producing butyrate. Blood markers like fasting glucose, HbA1c, and hs-CRP (high-sensitivity C-reactive protein, a measure of body-wide inflammation) round out the picture of whether your metabolism and immune system are feeling the effects.
If levels are unexpectedly high and you have known gum disease, kidney concerns, or a strong family history of kidney cancer, the pattern is worth investigating with a gastroenterologist or functional medicine provider who works with microbiome data. This is not a screening test for those conditions, but an unusual result in a relevant clinical context is worth a conversation.
Evidence-backed interventions that affect your Butyrivibrio Crossotus level
Butyrivibrio Crossotus is best interpreted alongside these tests.